Expectant management for men with early stage prostate cancer.
about
Targeted Prostate Biopsy: Lessons Learned Midst the Evolution of a Disruptive TechnologyQualitative insights into how men with low-risk prostate cancer choosing active surveillance negotiate stress and uncertaintyAberrant Protocadherin17 (PCDH17) Methylation in Serum is a Potential Predictor for Recurrence of Early-Stage Prostate Cancer Patients After Radical ProstatectomyToward ethically responsible choice architecture in prostate cancer treatment decision-making.Serial Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: Incremental ValueExpectant management of veterans with early-stage prostate cancer.Comparative effectiveness of prostate cancer treatments for patient-centered outcomes: A systematic review and meta-analysis (PRISMA Compliant)Cognitive and Affective Representations of Active Surveillance as a Treatment Option for Low-Risk Prostate Cancer.Texas Native Plants Yield Compounds with Cytotoxic Activities against Prostate Cancer Cells.Surgical Techniques for Managing Post-prostatectomy Erectile Dysfunction.A bioinformatics-to-clinic sequential approach to analysis of prostate cancer biomarkers using TCGA datasets and clinical samples: a new method for precision oncology?The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation.A prospective study of the short-term quality-of-life outcomes of patients undergoing transperineal prostate biopsy.Survival outcomes for patients with localised upper tract urothelial carcinoma managed with non-definitive treatment.Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study.
P2860
Q27008215-28E60D01-09C4-4410-B461-30295353802DQ33651148-23D1C803-E8E0-4284-8FDD-A7C108307779Q36399311-7171A0D7-56A5-41C0-9B38-06BF1F15F800Q36779782-68F50A71-6706-4BD8-A7AE-2892EE3CB514Q36988608-9EF1A493-07D1-4E9E-86EE-6592A5CDB619Q38626027-A173167C-E46A-452A-98EC-F90F35B0A708Q38804659-986D5471-2EFA-45E6-AEBD-F8C32179B444Q39640738-CDC5162B-8AF4-4781-8BEF-C0FE093EDC4CQ41186415-97C0FCAD-CA2B-489C-BE44-FA5F493B1933Q42368368-9B7E469A-FDAF-4311-A69D-B564171DB841Q47109041-B380FB07-2416-422F-A3FD-8278188F73AEQ47138098-06B8E6BB-F58F-444A-97E5-320795EEBB65Q47853134-30988AA0-457C-4B74-AE68-D8A0727A8C53Q47875264-FAA74E64-0AC1-446C-B81F-85DC5B0517E2Q55236981-3E1B1CC6-5BE6-4F0F-A6D0-9C186CCC2020
P2860
Expectant management for men with early stage prostate cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Expectant management for men with early stage prostate cancer.
@en
type
label
Expectant management for men with early stage prostate cancer.
@en
prefLabel
Expectant management for men with early stage prostate cancer.
@en
P2860
P356
P1433
P1476
Expectant management for men with early stage prostate cancer.
@en
P2093
Leonard S Marks
Mark S Litwin
P2860
P304
P356
10.3322/CAAC.21278
P407
P577
2015-05-08T00:00:00Z